Curing Diabetes With Stem Cells

|
Includes: LLY, MRK, NVO, SNY
by: ARK Investment Management

by James Bannon, ARK Analyst

New research out of Harvard University’s Stem Cell Institute may have cracked the code to curing diabetes. In a break-through study, scientists were able to turn human embryonic stem cells into fully mature insulin-producing beta cells and implant them into living tissue. While currently only in animals, these studies, if successful in humans, could point the way towards a cure for both Type 1 and Type 2 diabetes.

A major obstacle to a stem cell related cure is keeping the implanted cells alive. With Type 1 diabetes, the body’s immune system attacks insulin-producing cells, so the cure relies importantly on preserving the implanted healthy cells. It is difficult to determine if and when this problem will be solved, but there is hope for a solution. In San Diego, a clinical trial has begun using a different stem cell diabetes treatment. If these insulin-producing stem cells can be kept alive, then it is possible the Harvard cells can be kept alive as well. This may not be only obstacle encountered in the search for a stem cell related cure, and success may still be a long way off.

The Center for Disease Control (NASDAQ:CDC) estimates that 9% of the US population, or 29 million people, suffer from diabetes. In the US, the costs to treat diabetes can top $750 per month, not including the cost of co-morbidities like obesity and hypertension. The World Health Organization (WHO) estimates that the number of diabetes-related deaths could be as high as four million globally per year.

If a stem cell treatment succeeds, pharmaceutical revenues derived from diabetes treatments will be called into question. The top ten selling diabetes drugs in 2013 generated more than $28 billion in revenue, as shown below. All diabetes drugs generated more than $36 billion, and are projected to top $55 billion by 2023. A one-time cure would do wonders for those inflicted with diabetes currently relying on daily injections and glucose monitoring, and save the health care system tens of billions of dollars.

If stem cell treatment becomes viable, companies that derive significant revenue from diabetes, chief among them Sanofi (NYSE:SNY), Merck (NYSE:MRK), Eli Lilly (NYSE:LLY), and Novo Nordisk (NYSE:NVO), will be disintermediated. They should keep a close eye on the progress at Harvard’s Stem Cell Institute, and perhaps make contingency plans.

©2014, ARK Investment Management LLC. All content is original and has been researched and produced by ARK Investment Management LLC (“ARK”) unless otherwise stated. No part of this content may be reproduced in any form, or referred to in any other publication, without the express written permission of ARK. All statements made regarding companies, securities or other financial information on this site or any sites or articles relating to ARK are strictly beliefs and points of view held by ARK and are subject to change without notice. Certain of the statements contained in ARK original content may be statements of future expectations and other forward-looking statements that are based on ARK’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Information contained in ARK content has been obtained from sources believed to be reliable, but is not guaranteed. This content has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. Any reference to a particular company or security in ARK original content is not an endorsement by ARK of that company or security or a recommendation by ARK to buy, sell or hold any particular security. Investors should determine for themselves whether a particular service, strategy, product or security is suitable for their investment needs or should seek such professional advice for their particular situation. By visiting and/or otherwise using the ARK website in any way, you indicate that you understand and accept the terms of use as set forth on the website and agree to be bound by them. If you do not agree to the terms of use of the ARK website, please do no access the ARK website or any pages thereof.

About this article:

Expand
Tagged:
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here